Laronde is creating safer and effective 'Endless RNA' therapies
Chemical & Engineering News (C&EN) - 30-Aug-2021Raised $440m to advance e-RNA based medicine for a wide range of diseases
Join the club for FREE to access the whole archive and other member benefits.
CEO of Laronde and CEO-Partner at Flagship Pioneering
Diego Miralles is a veteran pharmaceutical and biotech leader who joined Flagship Pioneering in 2020, as CEO-Partner and CEO of Laronde. Prior to this role, Diego was a CEO of Vividion Therapeutics and President of Adaptive Therapeutics. He also worked at Johnson & Johnson, Tibotec, Trimeris, and Triangle Pharmaceuticals.
Diego received an M.D. from Universidad de Buenos Aires and conducted his residency at the Mayo Clinic in Rochester, Minn., and his fellowship in Infectious Diseases at New York Hospital-Cornell University Medical Center.
Visit website: https://www.laronde.bio/about#DiegoMiralles
See also: Laronde - A Flagship Pioneering company developing Endless RNA therapeutics
Details last updated 26-Dec-2021
Raised $440m to advance e-RNA based medicine for a wide range of diseases